SupportGroup031106

Information about SupportGroup031106

Published on May 2, 2008

Author: Janelle

Source: authorstream.com

Content

Radiation Oncology and Prostate Cancer Current Status and New Advances:  Radiation Oncology and Prostate Cancer Current Status and New Advances Ajay Sandhu M.D. Associate Professor, Radiation Oncology UCSD Moores Cancer Center Epidemiology:  Epidemiology ~ 200,000 cases/yr in US ~ 40,000 deaths ~ 15% lifetime risk of developing disease Risk increases with age ~ 80% chance of (+) bx by 80 yrs Most men die with prostate cancer, not of prostate cancer Risk Factors:  Risk Factors Family history of PCA (RR ~ 2.0) ~ 10% of all cases Race not an independent risk factor Unproven risk factors High dietary fat BPH (benign prostatic hypertrophy) Smoking Occupational factors Pathology & Histology:  Pathology & Histology Digital Rectal Exam limitations Prostatic biopsy (sampling issues) Gleason score Graded 1-5 based on microscopic patterns Scores range from 2-10 Prostate specimen:  Prostate specimen Screening:  Screening ACS and AUA Recommendation All men > 50 with an expected survival > 10 yrs should undergo an annual DRE and serum PSA What is PSA?:  What is PSA? Prostatic Specific Antigen (PSA) Protein, functions to liquefy seminal coagulum, made by both benign and cancerous prostate cells Normal levels < 4 ng/dl Biopsies of the prostate are recommended for PSA’s > 4 ng/dl CAUTION ABOUT PSA:  CAUTION ABOUT PSA 25% men with progressive cancer have NO rise in PSA ? PSA threshold for biopsy; more so for younger men Free PSA for higher sensitivity and specificity TREATMENT OPTIONS:  TREATMENT OPTIONS OBSERVATION SURGERY- Prostatectomy RADIOTHERAPY- conformal IMRT, Brachytherapy, combination HORMONES- Androgen deprivation CHEMOTHERAPY Comparison of Therapies:  Comparison of Therapies No Modern randomized trials 1982 randomized trial demonstrating advantage of RP never widely accepted and criticized Nonrandomized comparison showed similar results for similar cohorts of patients with uniform selection criteria Risk Stratification of PC:  Risk Stratification of PC Low risk: PSA <10, GS 2-6, T1-T2a Intermediate risk: PSA 10-20, GS 7, T2b High risk: PSA>20 or GS >7 or >T2b Radiation Oncology:  Radiation Oncology Radiation therapy has a long in the treatment of cancer 1st patient treated in 1896 within 2 months of the discovery of X-rays Wilhelm Roentgen (1845-1923) Discovers X-rays in 1895 Radiation Oncology:  Radiation Oncology Radiation kills tumor cells by damaging DNA RadiationFree radicals (OH)  DNA breaks DNA breaks prevent the replication of DNA Irradiated cells ultimately die when attempting to divide (“reproductive death”) Radiation dose was given previously in “rads” Today it is given in “Gray” (1 Gy=100 rads) Slide18:  Radiation Modalities Teletherapy  “Therapy at a distance” (external beam RT) Involves the use of photons and electrons Brachytherapy “Close therapy” The use of radioactive sources (Cs137, Ir192, I125) placed either in a cavity (intracavitary) or within (interstitial) a tumor Slide19:  Radiation Therapy and Prostate Cancer First used to treat prostate cancer in 1909 (Pasteau) Radium capsules inserted into the urethra (intracavitary brachytherapy) Teletherapy machines of the day could not produce sufficiently penetrating beams London (1920) Slide20:  External Beam Treatment Machines 1920’s Low energy Poor penetration Unable to treat the prostate without skin toxicity 1950s Moderate Energy Improved penetration Less skin toxicity 1990s Computer controlled Linear accelerators Multiple high energy beams IMRT capable Slide21:  External Beam Prostate RT Initially a four field technique was used (anterior-posterior and 2 lateral fields) Field edges were shaped to minimize the dose to bladder and rectum Daily treatments lasting ~ 8 weeks Conventional 4 field prostate RT Standard 4 field pelvic plan:  Standard 4 field pelvic plan Intensity Modulated RT:  Intensity Modulated RT Unlike conventional RT, IMRT conforms the dose to the shape of the target in 3 dimensions IMRT uses a sophisticated planning software to divide each beam into thousands of “beamlets” with different intensities IMRT is delivered using machines equipped with “multi-leaf” collimators which move in and out of the beams path Modern linear accelerator head:  Modern linear accelerator head Slide26:  Conventional RT field with shaped edges The beam has equal intensity across its surface IMRT field divided into different “beamlets” Each pixel has a different intensity Slide27:  Intensity Modulated Radiation Therapy The intensity of each beam is modulated by moving the multi-leaf collimators in and out of the beam’s path The longer the leaves stay open in a particular position the higher the intensity of the radiation to that spot Multiple angles used in IMRT:  Multiple angles used in IMRT Machine eye view:  Machine eye view Better conformity with IMRT:  Better conformity with IMRT bladder prostate rectum Seminal vesicles Slide31:  IMRT in Prostate Cancer Reduces the dose to the bladder, rectum and femoral heads thereby minimizing the risk of injury to those organs Moreover, it provides the ability to dose escalate to 80 Gy+ Conventional RT IMRT Plan bladder prostate rectum Organ preservation:  Organ preservation Breast Larynx Tongue GI cancers Extremity Prostate? Early Stage Prostate Cancer Long-term biochemical disease control:  Early Stage Prostate Cancer Long-term biochemical disease control n Endpoint 10-year Result External Beam RT Mass General 1396 PSA Control* 42% MD Anderson 643 PSA Control* 61%*** Fox Chase 408 PSA Control** 59%*** Radical Prostatectomy Mayo Clinic 3170 PSA <2 µg/L 52% Washington University 925 PSA <6 µg/L 61% Johns Hopkins 2404 PSA <2 µg/L 74% *Defined as PSA <10 µg/L and absence of 2 rises after a nadir **Absence of 3 consecutive rises after a nadir ***8-year results Slide34:  Prostate IMRT Higher doses possible with IMRT may even result in better PSA control rates Zelefsky et al. (Memorial Sloan Kettering) Int J Radiat Oncol Biol Phys (2002) Favorable n=275 Intermediate n=322 Unfavorable n=175 External Beam RT:  External Beam RT Toxicity data compiled from 526 patients treated with external beam RT on two national protocols Most toxicities involve the rectum and bladder Any Moderate-Severe Diarrhea 12.7% 7.8% Proctitis 9.9% 6.3% Rectal Bleed 8.7% 3.1% Rectal-anal stricture 4.4% 1.5% Rectal Ulcer 1.1% 1.1% SBO 0.6% 0.6% Cystitis 11.4% 4.6% Hematuria 5.7% 3.6% Any severe GI-related (3.3%) and GU-related (7.7%) Lawton et al. Int J Radiat Oncol Biol Phys 1991;21:935 Pilepich et al. Int J Radiat Oncol Biol Phys 1987;13:351 Slide36:  Prostate IMRT IMRT may help to further risk of GI toxicity especially in patients treated to high doses Total dose = 81 Gy Grade  2 Bladder Rectum Acute Chronic Acute Chronic 3DCRT 37% 7% 61% 13% IMRT 44% 9% 45% 0.5% p-value NS NS 0.05 0.0001 Zelefsky et al. (Memorial Sloan Kettering) Radiotherapy Oncology (2000) Update J Urology (2001): 3-yr g2 chronic rectal 2 vs 14%, p < 0.0001 Slide37:  Prostate IMRT IMRT can also high doses to the “penile bulb” Sethi et al. (Loyola) Red J (2003) Dose (mean) Corpora cavernosa 51% Penile Bulb 47% without compromising prostate dose Clinical data needed to determine whether this approach reduces the risk of impotency Androgen Deprivation:  Androgen Deprivation Combined Androgen Blockade Intermittent ADT Neoadjuvant ADT Concurrent ADT Long-term Androgen Deprivation Rising PSA after RP:  Rising PSA after RP RP therapeutic goal : undetectable PSA 25-50% develop PSA elevation after RP with 77% of these within first 2 years Salvage RT more effective for positive margins, PSA<2.0 and longer PSA doubling time (>10 months) RT after RP:  RT after RP Capsule perforation, positive margins or invasion of seminal vesicle Adjuvant or Salvage Two randomized trials have shown earlier the better Improved biochemical disease free survival and local control; not overall survival Long term quality of life not adverse with RT Palliative RT:  Palliative RT Beneficial in controlling painful metastatic sites Improvement is seen in 80-90% of patients, many experience complete relief Treatment lasts 10 days (total dose, 30 Gy) An alternative is the radionuclide strontium-89 Sr-89 is given i.v. and is useful in pts with multiple painful sites Benefit is seen in 80-85% of patients Tong et al. Cancer 1982;50:893 Blitzer et al. Cancer 1985;55:1468 Turner et al. Br J Cancer 2002;84:297 Side Effects of Therapy:  Side Effects of Therapy Urinary incontinence 9.6% vs 3.5% Erectile Dysfunction 80% vs 60% for surgery vs RT Diarrhea, bowel urgency, painful hemorrhoids double in RT vs S Source: PCOS Conclusions:  Conclusions Radiation therapy has a long history in the treatment of prostate cancer Many of its early pioneers were famous urologists including Hugh Hampton Young Older techniques were not effective, modern brachytherapy and external beam approaches are associated with high cure rates with low rates of toxicity (IMRT) RT is also an effective approach in patients who relapse following surgery and those with painful metastatic disease sites

Related presentations


Other presentations created by Janelle

web2001 5 potato fungicide
31. 12. 2007
0 views

web2001 5 potato fungicide

Acupuncture
04. 01. 2008
0 views

Acupuncture

Networking Devices
01. 01. 2008
0 views

Networking Devices

Som de Cinema
24. 10. 2007
0 views

Som de Cinema

Cataract  History  05
02. 05. 2008
0 views

Cataract History 05

GEC NEVC 0ct 06
28. 09. 2007
0 views

GEC NEVC 0ct 06

LECTURE 7
03. 10. 2007
0 views

LECTURE 7

TS2 2 1
04. 10. 2007
0 views

TS2 2 1

saferoom
07. 10. 2007
0 views

saferoom

cpt
16. 10. 2007
0 views

cpt

Presentation media use
17. 10. 2007
0 views

Presentation media use

MosbysNursingCONSULT Training
29. 09. 2007
0 views

MosbysNursingCONSULT Training

maws3 5883
23. 10. 2007
0 views

maws3 5883

Presentacion PPP Panama
22. 10. 2007
0 views

Presentacion PPP Panama

sankar jag
29. 10. 2007
0 views

sankar jag

G020213 00
29. 10. 2007
0 views

G020213 00

jan20wrf
03. 10. 2007
0 views

jan20wrf

Contexto Latinoamericano 2005
22. 10. 2007
0 views

Contexto Latinoamericano 2005

BLRB08 2 rbs
11. 12. 2007
0 views

BLRB08 2 rbs

CrystalPP
12. 10. 2007
0 views

CrystalPP

07 Pilz
19. 10. 2007
0 views

07 Pilz

Lec3 APS301 Slideshow
25. 10. 2007
0 views

Lec3 APS301 Slideshow

Hill Ch 003 part 3 03
31. 10. 2007
0 views

Hill Ch 003 part 3 03

Foolish Fragments
01. 11. 2007
0 views

Foolish Fragments

pp hematoma
06. 11. 2007
0 views

pp hematoma

file0068
06. 11. 2007
0 views

file0068

Biodiesel Production
07. 11. 2007
0 views

Biodiesel Production

turkey presentation
21. 11. 2007
0 views

turkey presentation

Turkey and the EU
23. 11. 2007
0 views

Turkey and the EU

chap14 07
14. 12. 2007
0 views

chap14 07

The Clash of Civilizations
23. 12. 2007
0 views

The Clash of Civilizations

grace agnew
20. 11. 2007
0 views

grace agnew

IX Aerosol
03. 01. 2008
0 views

IX Aerosol

Malignant Wounds
05. 01. 2008
0 views

Malignant Wounds

224 121676
07. 01. 2008
0 views

224 121676

Monday lab ppt presentation
10. 10. 2007
0 views

Monday lab ppt presentation

Sailor Relationship Management
08. 10. 2007
0 views

Sailor Relationship Management

Schischke Penang Label v2
01. 10. 2007
0 views

Schischke Penang Label v2

tomography
15. 10. 2007
0 views

tomography

Flowering2
17. 12. 2007
0 views

Flowering2

INMET training course v4
28. 12. 2007
0 views

INMET training course v4

landmarks And Monuments
12. 10. 2007
0 views

landmarks And Monuments

EARSS december 1 06
19. 10. 2007
0 views

EARSS december 1 06

Presen 1
10. 10. 2007
0 views

Presen 1

P6S1
16. 02. 2008
0 views

P6S1

mtgbog07 smith
19. 02. 2008
0 views

mtgbog07 smith

Viktoras Seskauskas
28. 11. 2007
0 views

Viktoras Seskauskas

Canadian literature powerpoint4
12. 03. 2008
0 views

Canadian literature powerpoint4

ses3 1545 Sethu Raman
30. 09. 2007
0 views

ses3 1545 Sethu Raman

A105 024 Cosmo
16. 10. 2007
0 views

A105 024 Cosmo

communication 2
27. 11. 2007
0 views

communication 2

Performance of DFT
31. 10. 2007
0 views

Performance of DFT

investment strategy
09. 04. 2008
0 views

investment strategy

Analyst meet
17. 04. 2008
0 views

Analyst meet

Sess 1 Zhang Xizhen
10. 10. 2007
0 views

Sess 1 Zhang Xizhen

2205 Joao Carlos
26. 11. 2007
0 views

2205 Joao Carlos

Single Payer101
07. 05. 2008
0 views

Single Payer101

dentalhealth
08. 05. 2008
0 views

dentalhealth

AACBelecs2004
08. 05. 2008
0 views

AACBelecs2004

Extending the SpanishWordNet
31. 10. 2007
0 views

Extending the SpanishWordNet

SCOPE991001
02. 05. 2008
0 views

SCOPE991001

Martina OConnor
02. 05. 2008
0 views

Martina OConnor

dns pres michaelson roots
30. 10. 2007
0 views

dns pres michaelson roots

m101
09. 10. 2007
0 views

m101

CaseEUvirtuellefabrik
15. 10. 2007
0 views

CaseEUvirtuellefabrik

hou leong
10. 10. 2007
0 views

hou leong

DeSangroValencia
31. 10. 2007
0 views

DeSangroValencia

Intro to Pod biomech
30. 04. 2008
0 views

Intro to Pod biomech

wspa07 23
26. 03. 2008
0 views

wspa07 23

95 Romi 25mag
19. 10. 2007
0 views

95 Romi 25mag

Tue1530 137
09. 10. 2007
0 views

Tue1530 137

Helping students help themselves
30. 10. 2007
0 views

Helping students help themselves

XPath
18. 10. 2007
0 views

XPath

GSB presentation4
29. 12. 2007
0 views

GSB presentation4

tornado sample slides
02. 10. 2007
0 views

tornado sample slides

vbq
09. 10. 2007
0 views

vbq

sullivan list
08. 10. 2008
0 views

sullivan list

Moore Plasma Circulation ESSE06
02. 11. 2007
0 views

Moore Plasma Circulation ESSE06

biod145 lecture4 bb
16. 10. 2007
0 views

biod145 lecture4 bb

Final Spring 2003 Presentation
06. 03. 2008
0 views

Final Spring 2003 Presentation

Provisu SSIM2006
19. 10. 2007
0 views

Provisu SSIM2006

WDHSJuly505
20. 02. 2008
0 views

WDHSJuly505

30th Anniv USSP
17. 10. 2007
0 views

30th Anniv USSP

Prion2005
15. 10. 2007
0 views

Prion2005

imperialism 2
22. 10. 2007
0 views

imperialism 2

Lipchitz AFDonCatRisk
23. 10. 2007
0 views

Lipchitz AFDonCatRisk

Cumberland
26. 11. 2007
0 views

Cumberland

606
16. 11. 2007
0 views

606

GAIC5Oct04
31. 10. 2007
0 views

GAIC5Oct04

eceatcz
20. 03. 2008
0 views

eceatcz

upa nyc jonathan bloom
04. 10. 2007
0 views

upa nyc jonathan bloom

ssuo robo3
15. 11. 2007
0 views

ssuo robo3

nuccio lanza
15. 11. 2007
0 views

nuccio lanza

Haroldo Sustainab Develop 0607
30. 10. 2007
0 views

Haroldo Sustainab Develop 0607

presentation eichhorn jan
16. 11. 2007
0 views

presentation eichhorn jan

ling411 23
19. 11. 2007
0 views

ling411 23

DYB US PRC
16. 10. 2007
0 views

DYB US PRC

PHN0202a
13. 03. 2008
0 views

PHN0202a

10 2205 HISTORIA EUA
13. 11. 2007
0 views

10 2205 HISTORIA EUA

ChineseAmericans
30. 10. 2007
0 views

ChineseAmericans

apgrid ggf4
09. 10. 2007
0 views

apgrid ggf4

kur
26. 10. 2007
0 views

kur

HIS104 Lecture05
31. 10. 2007
0 views

HIS104 Lecture05

Harvard Presentation
12. 10. 2007
0 views

Harvard Presentation

wilhelmson
02. 10. 2007
0 views

wilhelmson

MLI Site Visit 4 98 overview
29. 09. 2007
0 views

MLI Site Visit 4 98 overview